Growing Prevalence of Bleeding Disorders and Advancements in Treatments to Bolster Market Revenue; Reaching USD 19.9 Bn: Report Fact.MR

News Source: Fact.MR
2022-07-18 16:11
SEOUL--(Korea Newswire) July 18, 2022 -- As per an in-depth industry analysis on bleeding disorders treatment by Fact.MR, market research and competitive intelligence provider, the global market is anticipated to expand at a CAGR of 6.7% over the forecast period of 2021-2027, reaching USD 19.9 Bn at the end of this period.

The geriatric population is driving demand for bleeding disorders treatment, because changes in renal function, immunological modulation, and a variety of other disease processes that occur with aging can lead to acquired bleeding disorders.

Another key element that will contribute to the growth of the bleeding disorders treatment market is increased awareness of genetic illnesses. Other factors such as an increase in the number of diagnostic laboratories, hospitals, and treatment centers, among others, would contribute to worldwide bleeding disorders treatment market growth.

The market has grown in response to increased knowledge, demand, and preference for preventative therapy. The prevalence of liver illnesses, anemia, and other blood coagulation disorders is increasing, which will also drive the need for bleeding disorders treatments.

What elements can have a positive impact on the demand for medications used to treat bleeding disorders?

An increase in the population with bleeding disorders is driving the demand for treatments for these conditions. Over 1,125,000 boys worldwide suffer from a genetic bleeding disorder, of which 418,000 have a mild variety that is frequently undiagnosed. The market for treating bleeding disorders has been expanding as a result of the large number of patients who are receiving therapy in some capacity.

In an effort to increase patient understanding of therapy and adoption rates, numerous businesses and academic institutions have been attempting to create new medications and enhance existing ones.

The delivery of many replacement drugs has improved, and their potency, immunogenicity, and half-lives have all increased. For the past five years, improvements in bioengineering have benefited the treatment of disorders that cause bleeding. In the upcoming years, these advancements are anticipated to lead to an increase in the market for treating bleeding disorders.

Report Attributes for Bleeding Disorders Treatment Market

Report Attributes / Details
Bleeding Disorders Treatment Market Size (2020) / USD 12.7 Bn
Projected Year Value (2027) / USD 19.9 Bn
Global Market Growth Rate (2021-2027) / 6.7% CAGR
China Market Growth Rate (2021-2027) / 10.1%

Key Takeaways from Market Study

· Global bleeding disorders treatment market to reach USD 19.9 Bn by 2027.
· Hemophilia A projected to reach a valuation of around USD 11.1 Bn by 2027.
· Market in Canada to record 6% CAGR over the forecast period of 2021-2027.
· Market in Asia Pacific forecast to reach USD 2.7 Bn by 2027.

“As people become more aware of the need to treat various types of bleeding disorders, the bleeding disorders treatment market is expected to rise at a rapid pace. Increased research and development initiatives for the treatment of many types of blood disorders will fuel market revenue,” says a Fact.MR analyst.

Key Segments of Bleeding Disorders Treatment Industry Research

· Bleeding Disorders Treatment Market by Type:
-Hemophilia A
-Hemophilia B
-Other Types

· Bleeding Disorders Treatment Market by Drug Class:
-Plasma-derived Coagulation Factor Concentrates
-Recombinant Coagulation Factor Concentrates
-Fibrin Sealants
-Other Drug Classes

Winning Strategy

Key companies are focusing on strategic company expansions and innovative product releases to increase their position in the global market. Market players rely on a variety of techniques, including product releases and approvals. Mergers, acquisitions, and alliances are common growth methods used by these companies. Prominent players are boosting their share in the bleeding disorders treatment market with the use of these techniques.

For instance,

· In February 2020, Novo Nordisk announced the launch of a new medicine called “ESPEROCT®”. The company's long-acting recombinant factor V111 product is now available for the prevention and treatment of bleeding in people with Hemophilia A. Throughout all clinical trials, the new medicine was shown to be safe and well-tolerated.
· In November 2021, Genentech announced that data from its hematology portfolio would be presented at the ASH (American Society of Hematology) Annual Meeting and Exposition, which covers a wide range of bleeding disorders such as hemophilia.

More Valuable Insights on Offer

Fact.MR, in its new offering, presents an unbiased analysis of the global bleeding disorders treatment market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2027.

The study divulges essential insights on the market on the basis of type (hemophilia A, hemophilia B, and other types) and drug class (plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, fibrin sealants, and other drug classes), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Media Contact: Fact.MR   Mahendra Singh   +353-1-4434-232 (D)  
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.   배포 안내 >
같은 분야 보도자료 보기
  • 이 보도자료를 공유하세요
  • Growing Prevalence of Bleeding Disorders and Advancements in Treatments to Bolster Market Revenue; Reaching USD 19.9 Bn: Report Fact.MR
주제별 보도자료
지역별 보도자료
더 알아보기